United States

People: Celgene Corp (CELG.O)

CELG.O on Nasdaq

27 Feb 2017
Change (% chg)

$3.55 (+3.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hugin, Robert 

Mr. Robert J. Hugin serves as Executive Chairman of the Board of the Company., effective March 1, 2016. He is no longer Chief Executive Officer of Celgene Corp. He also served as our Chief Operating Officer from May 1, 2006 until June 16, 2010 and Senior Vice President and Chief Financial Officer from June 1999 until May 1, 2006. Mr. Hugin has served as one of our directors since December 2001. Previously, Mr. Hugin had been a Managing Director at J.P. Morgan & Co. Inc., which he joined in 1985. Mr. Hugin received an A.B. degree from Princeton University and an M.B.A. from the University of Virginia. Mr. Hugin is also a director of The Medicines Company, Atlantic Health System, Inc., a non-profit health care system, and Family Promise, a national non-profit network assisting homeless families. Mr. Hugin brings to his role as a director his extensive executive and leadership experience at Celgene and his previous business experience, as well as his leadership roles on the boards of a public company and a non-profit health care company. In particular, his experience as our President, Chief Operating Officer and Chief Financial Officer and his current role as our Chief Executive Officer enable him to provide leadership and unique insight on complex business and financial matters and guidance with respect to the strategic goals and operating framework of a high growth company such as ours. Additionally, Mr. Hugin served as Chairman of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) from April 2013 until April 2014, is a past Chairman of the HealthCare Institute of New Jersey and is a member of the Board of Trustees of Princeton University.

Basic Compensation

Total Annual Compensation, USD 8,853,440
Restricted Stock Awards, USD 5,431,240
Long-Term Incentive Plans, USD --
All Other, USD 8,188,240
Fiscal Year Total, USD 22,472,900

Options Compensation

  Quantity Market Value
Exercisable 2,998,286 60,442,600.00
Unexercisable 11,667 --
Exercised 378,592 34,809,000.00
Name Fiscal Year Total

Robert Hugin


Jacqualyn Fouse


Mark Alles


Peter Kellogg


Thomas Daniel


Scott Smith

As Of  30 Dec 2015